Drug intelligence / Profile preview

pemafibrate + fluconazole

Development stage: Unknown
Lead developer: Kowa
Modality: Small Molecules
Administration: Oral

Overview

This is an unapproved combination of two drugs: **pemafibrate** (code name K-877), a highly selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) used for atherogenic dyslipidemia, and **fluconazole**, a widely used triazole antifungal agent. There is no evidence in the literature or clinical practice describing this combination for a specific indication. Pemafibrate acts primarily on lipid metabolism and inflammation, while fluconazole inhibits fungal ergosterol biosynthesis by targeting lanosterol 14α-demethylase, thus disrupting cell membrane formation in fungi[2][4][5].

Brand names: ParmodiaDiflucan
Other names: pemafibrateK-877K877K 877fluconazole

Targets

CYP51A1 (Sterol 14α-demethylase)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on pemafibrate + fluconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pemafibrate + fluconazole.

Explore the full profile